Ashok Chakraborty* and Anil Diwan

Department of Cell Biology, AllExcel, Inc, Shelton, CT, USA

*Corresponding Author: Ashok Chakraborty, Department of Cell Biology, AllExcel, Inc, Shelton, CT, USA.

Received: July 19,2022; Published: September 15, 2022

Abstract

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease (MND) with the worst prognosis with 4-5 years. Both upper and lower motor neurons in the cortex and in the brainstem spinal cord are affected. No effective treatments are available yet. Furthermore, in 10-14% ALS cases are involved with genetic defects, while about 90% cases are reported as sporadic. In fact, immune dysregulation causes the activation of inflammatory cells that augment the ALS disease progression. M2 macrophages have immunosuppressive activity, produces high level of anti-inflammatory cytokine IL-10 and mediates tissue repair, noticed in diabetic and nephrotic mice. The M1-type of macrophages (MΦs), are pro-inflammatory and causes lung disease, like ALI (acute lung injury) and ARDS (acute respiratory distress syndrome). Recently, it was demonstrated that M2-type of MΦs are immunosuppressive, can induce boost Tregs (Regulatory T cells), and serves as a candidate for immune-cell-based therapy for ALS.

In this review we drew a hypothetical connection, supported by evidence, between nanoparticles medicated MFs polarization to M2 type and targeting to deliver in the brain for ALS control.

Keywords: ALS Disease; Motor Neuron Defects; MQ Polarization; Nanobiopolymer

References

1. Appel SH., et al. “T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?” Trends in Immunology 31 (2010): 7-17.
2. Appel SH., et al. “The microglial-motor neuron dialogue in ALS”. Acta Myologica 30 (2011): 4-8.
3. Beers DR and Appel SH. “Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies”. The Lancet Neurology 18 (2019): 211-220.
4. Butovsky O and Weiner HL. “Microglial signatures and their role in health and disease”. Nature Reviews Neuroscience 19 (2018): 622-635.
5. Keizman D., et al. “Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis”. Acta Neurologica Scandinavica 119 (2009): 383-389.
6. Zhao W., et al. “Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes”. JAMA Neurology 74 (2017) :677-685.
7. Hu Y., et al. “Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study”. Scientific Reports 7 (2017): 9094.
8. Beers DR., et al. “CD4+ T-cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS”. Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 15558-15563.

9. Chiu IM., et al. “T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS”. Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 17913-17918.

1. Grassivaro F., et al. “Convergence between microglia and peripheral macrophages phenotype during development and neuroinflammation”. Journal of Neuroscience 40 (2020): 784-795.
2. Ajami B., et al. “Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models”. Nature Neuroscience 21 (2018) :541-551.
3. Ransohoff RM. “A polarizing question: do M1 and M2 microglia exist?” Nature Neuroscience19 (2016): 987-991.
4. Gordon S and Taylor PR. “Monocyte and macrophage heterogeneity”. Nature Reviews Immunology 5 (2005): 953-964.
5. Thompson BT., et al. “Acute respiratory distress syndrome”. The New England Journal of Medicine 377 (2017): 562-572.
6. Murray PJ and Wynn TA. “Obstacles and opportunities for understanding macrophage polarization”. Journal of Leukocyte Biology 89 (2011): 557-563.
7. Murray PJ and Wynn TA. “Protective and pathogenic functions of macrophage subsets”. Nature Reviews Immunology 11 (2011): 723-737.
8. Bai L., et al. “M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes”. Scientific Reports 7 (2017): 10518.
9. Cherry JD., et al. “Neuroinflammation and M2 microglia: the good, the bad, and the inflamed”. Journal of Neuroinflammation 11 (2014): 98-110.
10. Huang X., et al. “The role of macrophages in the pathogenesis of ALI/ARDS”. Mediators of Inflammation 2018 (2018): 1264913.
11. Lu HL., et al. “Activation of M1 mac- rophages plays a critical role in the initiation of acute lung injury”. Bioscience Reports 38 (2018): BSR20171555.
12. Robinson BD., et al. “Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination”. Clinical Cancer Research 15 (2009): 2433-2441.
13. Sun Y., et al. “Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B”. Nature Medicine 18 (2012): 1359.
14. Principe DR., et al. “TGFbeta Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis”. Cancer Research 76 (2016): 2525-2539.
15. Ma X., et al. “Definition of Prostaglandin E₂-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth”. Cancer Research 75 (2015): 2822-2832.
16. Arora S., et al. “Macrophages: their role, activation and polarization in pulmonary diseases”. Immunobiology 223 (2018): 383-396.
17. D’Alessio FR., et al. “Enhanced resolution of experimental ARDS through IL-4-mediated lung macrophage reprogramming”. The American Journal of Physiology-Lung Cellular and Molecular Physiology 310 (2016): L733-746.
18. Ying W., et al. “Investigation of mac- rophage polarization using bone marrow derived macrophages”. Journal of Visualized Experiments 23 (2013): 50323.
19. Murray PJ. “Macrophage polarization”. Annual Review of Physiology 79 (2017): 541-566.

29. Yang BY., et al. “Porous Se@SiO2 nanosphere-coated catheter accelerates prostatic urethra wound healing by modulating macrophage polarization through reactive oxygen species-NF-kappa B pathway inhibition”. Acta Biomaterialia 88 (2019): 392-405.
30. Malashchenko VV., et al. “Direct anti-inflammatory effects of granulocyte colony-stimulating factor (G-CSF) on activation and functional properties of human T cell subpopulations in vitro”. Cellular Immunology325 (2018): 23-32.
31. Sun T., et al. “Engineered nanoparticles for drug delivery in cancer therapy”. Angewandte Chemie 53 (2014): 12320-12364.
32. Nguyen TX., et al. “Recent advances in liposome surface modification for oral drug delivery”. 11 (2016): 1169-1185.
33. Ren H., et al. “Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy”. ACS Applied Materials and Interfaces 11 (2019): 20304-20315.
34. Rao W., et al. “Chitosan- decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells”. ACS Nano 9 (2015): 5725-5740.
35. Danhier F., et al. “PLGA-based nanoparticles: an overview of biomedical applications”. Journal of Controlled Release 161 (2012): 505-522.
36. Acharya S and Sahoo SK. “PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect”. Advanced Drug Delivery Reviews 63 (2011): 170-183.
37. Ma L., et al. “Efficient targeting of adipose tissue macrophages in obesity with polysaccharide nanocarriers”. ACS Nano 10 (2016): 6952-6962.
38. Diab R., et al. “Silica-based systems for oral delivery of drugs, macromolecules and cells”. Advances in Colloid and Interface Science 249 (2017): 346-362.
39. Mody VV., et al. “Introduction to metallic nanoparticles”. Journal of Pharmacy and Bioallied Sciences 2 (2010): 282-289.
40. Jain S., et al. “Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis”. Biomaterials 61 (2015): 162-177.
41. Xiong Y., et al. “Peptide-gold nanoparticle hybrids as promising anti-inflammatory nanotherapeutics for acute lung injury: in vivo efficacy, biodistribution, and clearance”. Advanced Healthcare Materials 7 (2018): e1800510.
42. Pang L., et al. “Exploiting macrophages as targeted carrier to guide nanoparticles into glioma”. Oncotarget 7 (2016): 37081-37091.
43. Matsumura Y and Maeda H. “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs”. Cancer Research 12 Pt 1 (1986): 6387-6392.
44. Pustylnikov S., et al. “Targeting the C-type lectins- mediated host-pathogen interactions with dextran”. Journal of Pharmacy and Pharmaceutical Sciences 17 (2014): 371-392.
45. Moghimi SM., et al. “Nanomedicine: current status and future prospects”. FASEB Journal 19 (2005): 311-330.
46. Bao G., et al. “Multifunctional nanoparticles for drug delivery and molecular imaging”. Annual Review of Biomedical Engineering 15 (2013): 253-282.
47. Matoba T., et al. “Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease”. J-Card 70 (2017): 206-211.
48. Jung M., et al. “Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2”. Kidney International 81 (2012): 969-982.
49. Stout RD., et al. “Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences”. The Journal of Immunology 175 (2005): 342-349.
50. Wang Y., et al. “Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease”. Kidney International 72 (2007): 290-299.
51. Acarregui A., et al. “Multifunctional hydrogelbased scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response”. Acta Biomaterialia 10 (2014): 4206-4216.
52. Gurruchaga H., et al. “Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin”. International Journal of Pharmaceutics 485 (2015): 15-24.
53. Del Burgo LS., et al. “Hybrid alginate-protein-coated graphene oxide microcapsules enhance the functionality of erythropoietin secreting C₂C₁₂ myoblasts”. Molecular Pharmacology 14 (2017): 885-98.
54. Sola A., et al. “Microencapsulated macrophages releases conditioned medium able to prevent epithelial to mesenchymal transition”. Drug Delivery 25:1 (2018): 91-101.
55. Iwasaki A and Medzhitov R. “Regulation of Adaptive Immunity by the Innate Immune System”. Science 327 (2010): 291-295.
56. Sica A and Mantovani A. “Macrophage plasticity and polarization: in vivo veritas”. Journal of Clinical Investigation 122 (2012): 787-795.
57. Mantovani A., et al. “Macrophage polarization comes of age”. Immunity 23 (2005): 344-346.
58. MantovaniA., et al. “The chemokine system in diverse forms of macrophage activation and polarization”. Trends in Immunology 25 (2004): 677-686.

Citation

Citation: Ashok Chakraborty and Anil Diwan. “Biopolymer Mediated Macrophage Polarization: A Method of ALS (Amyotropic Lateral Sclerosis) Control”. Acta Scientific Neurology 5.10 (2022): 19-24.

Copyright

Copyright: © 2022 Ashok Chakraborty and Anil Diwan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.